Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 and keeps a Buy rating on the shares. The firm is updating its model after the company’s FY24 results and FY25 guidance as the company management anticipates ongoing topline growth from Jaypirca, Ebglyss, Omvoh and Kisunla and Mounjaro market expansion, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Wells downgrades Vertex to Equal Weight on lack of catalysts
- RFK Jr. comments contradict anti-vaccine legacy, says Truist
- OnKure Therapeutics initiated with a Buy at JonesResearch
- Leerink says Eli Lilly news causes concern about Tectonic’s TX45 success
- BeyondSpring to sell portion of equity interest in SEED for $35.4MEli Lilly
Questions or Comments about the article? Write to editor@tipranks.com